Cardiac Mapping Market Research Report - Forecast till 2027

Cardiac Mapping Market : Information By Product (Contact Cardiac Mapping Systems, Non-Contact Cardiac Mapping Systems), By Indication (Atrial Fibrillation, Atrial Flutter, Avnrt And Others), By End User (Hospitals, Clinics, Diagnostic Centers) - Forecast Till 2027

ID: MRFR/HC/7314-HCR | February 2021 | Region: Global | 125 Pages         

Table of Contents

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Primary Research

3.3. Secondary Research

3.4. Market Size Estimation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Porter’s Five Forces Analysis

5.1.1. Bargaining Power of Suppliers

5.1.2. Bargaining Power of Buyers

5.1.3. Threat of New Entrants

5.1.4. Threat of Substitutes

5.1.5. Intensity of Rivalry

5.2. Value Chain Analysis/Supply Chain Analysis

6. GLOBAL CARDIAC MAPPING MARKET, BY PRODUCT

6.1. Overview

6.2. Contact Cardiac mapping systems

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3. Non-contact Cardiac mapping systems

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7. GLOBAL CARDIAC MAPPING MARKET, BY INDICATION

7.1. Overview

7.2. Atrial Fibrillation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3. Atrial Flutter

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4. AVNRT

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5. Wolff-Parkinson-White Syndrome (WPW)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6. Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8. GLOBAL CARDIAC MAPPING MARKET, BY END USER

8.1. Overview

8.2. Hospitals

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3. Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4. Diagnostic Centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

9. GLOBAL CARDIAC MAPPING MARKET, BY REGION

9.1. Overview

9.2. Americas

9.2.1. North America

9.2.1.1. US

9.2.1.2. Canada

9.2.2. Latin America

9.3. Europe

9.3.1. Western Europe

9.3.1.1. Germany

9.3.1.2. France

9.3.1.3. Italy

9.3.1.4. Spain

9.3.1.5. UK

9.3.1.6. Rest of Western Europe

9.3.2. Eastern Europe

9.4. Asia-Pacific

9.4.1. Japan

9.4.2. China

9.4.3. India

9.4.4. Australia

9.4.5. South Korea

9.4.6. Rest of Asia-Pacific

9.5. Middle East & Africa

9.5.1. Middle East

9.5.2. Africa

10. COMPANY LANDSCAPE

10.1.1. Overview

10.1.2. Competitive Analysis

10.1.3. Market Share Analysis

10.1.4. Major Growth Strategy in the global cardiac mapping market

10.1.5. Competitive Benchmarking

10.1.6. Leading Player in terms of Number of Developments in the global cardiac mapping market

10.1.7. Key Developments & Growth Strategies

10.1.7.1. Product Launch

10.1.7.2. Merger & Acquisition

10.1.7.3. Joint Ventures

10.1.8. Major Players Financial Matrix

10.1.8.1. Sales & Operating Income 2020

10.1.8.2. Major Players R&D Expenditure 2020

11. COMPANY PROFILES

11.1. Abbott Laboratories

11.1.1. Company Overview

11.1.2. Product Type Overview

11.1.3. Financial Overview

11.1.4. Key Developments

11.1.5. SWOT Analysis

11.1.6. Key Strategies

11.2. GE Healthcare

11.2.1. Company Overview

11.2.2. Product Type Overview

11.2.3. Financial Overview

11.2.4. Key Developments

11.2.5. SWOT Analysis

11.2.6. Key Strategies

11.3. Hill-Rom Services, Inc.

11.3.1. Company Overview

11.3.2. Product Type Overview

11.3.3. Financial Overview

11.3.4. Key Developments

11.3.5. SWOT Analysis

11.3.6. Key Strategies

11.4. Medtronic plc.

11.4.1. Company Overview

11.4.2. Product Type Overview

11.4.3. Financial Overview

11.4.4. Key Developments

11.4.5. SWOT Analysis

11.4.6. Key Strategies

11.5. Koninklijke Philips N.V.

11.5.1. Company Overview

11.5.2. Product Type Overview

11.5.3. Financial Overview

11.5.4. Key Developments

11.5.5. SWOT Analysis

11.5.6. Key Strategies

11.6. Biotronik

11.6.1. Company Overview

11.6.2. Product Type Overview

11.6.3. Financial Overview

11.6.4. Key Developments

11.6.5. SWOT Analysis

11.6.6. Key Strategies

11.7. Boston Scientific Corporation

11.7.1. Company Overview

11.7.2. Product Type Overview

11.7.3. Financial Overview

11.7.4. Key Developments

11.7.5. SWOT Analysis

11.7.6. Key Strategies

11.8. LivaNova plc

11.8.1. Company Overview

11.8.2. Product Type Overview

11.8.3. Financial Overview

11.8.4. Key Developments

11.8.5. SWOT Analysis

11.8.6. Key Strategies

11.9. Nihon Kohden Corporation

11.9.1. Company Overview

11.9.2. Product Type Overview

11.9.3. Financial Overview

11.9.4. Key Developments

11.9.5. SWOT Analysis

11.9.6. Key Strategies

11.10. Schiller AG

11.10.1. Company Overview

11.10.2. Product Type Overview

11.10.3. Financial Overview

11.10.4. Key Developments

11.10.5. SWOT Analysis

11.10.6. Key Strategies

11.11. Johnson & Johnson

11.11.1. Company Overview

11.11.2. Product Type Overview

11.11.3. Financial Overview

11.11.4. Key Developments

11.11.5. SWOT Analysis

11.11.6. Key Strategies

11.12. Siemens Healthineers

11.12.1. Company Overview

11.12.2. Product Type Overview

11.12.3. Financial Overview

11.12.4. Key Developments

11.12.5. SWOT Analysis

11.12.6. Key Strategies

11.13. Lepu Medical

11.13.1. Company Overview

11.13.2. Product Type Overview

11.13.3. Financial Overview

11.13.4. Key Developments

11.13.5. SWOT Analysis

11.13.6. Key Strategies

11.14. Coremap

11.14.1. Company Overview

11.14.2. Product Type Overview

11.14.3. Financial Overview

11.14.4. Key Developments

11.14.5. SWOT Analysis

11.14.6. Key Strategies

11.15. Kardium, Inc.

11.15.1. Company Overview

11.15.2. Product Type Overview

11.15.3. Financial Overview

11.15.4. Key Developments

11.15.5. SWOT Analysis

11.15.6. Key Strategies

11.16. Catheter Precision, Inc.

11.16.1. Company Overview

11.16.2. Product Type Overview

11.16.3. Financial Overview

11.16.4. Key Developments

11.16.5. SWOT Analysis

11.16.6. Key Strategies

11.17. Epmap-System

11.17.1. Company Overview

11.17.2. Product Type Overview

11.17.3. Financial Overview

11.17.4. Key Developments

11.17.5. SWOT Analysis

11.17.6. Key Strategies

12. APPENDIX

12.1. References

12.2. Related Reports


LIST OF TABLES

TABLE 1 GLOBAL CARDIAC MAPPING MARKET SYNOPSIS, 2020-2027

TABLE 2 GLOBAL CARDIAC MAPPING MARKET ESTIMATES & FORECAST, 2020-2027 (USD MILLION)

TABLE 3 GLOBAL CARDIAC MAPPING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 4 GLOBAL CARDIAC MAPPING MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 5 GLOBAL CARDIAC MAPPING MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 6 GLOBAL CARDIAC MAPPING MARKET, BY REGION, 2020-2027 (USD MILLION)

TABLE 7 NORTH AMERICA: CARDIAC MAPPING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 8 NORTH AMERICA: CARDIAC MAPPING MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 9 NORTH AMERICA: CARDIAC MAPPING MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 10 US: CARDIAC MAPPING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 11 US: CARDIAC MAPPING MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 12 US: CARDIAC MAPPING MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 13 CANADA: CARDIAC MAPPING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 14 CANADA: CARDIAC MAPPING MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 15 CANADA: CARDIAC MAPPING MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 16 LATIN AMERICA: CARDIAC MAPPING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 17 LATIN AMERICA: CARDIAC MAPPING MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 18 LATIN AMERICA: CARDIAC MAPPING MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 19 EUROPE: CARDIAC MAPPING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 20 EUROPE: CARDIAC MAPPING MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 21 EUROPE: CARDIAC MAPPING MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 22 WESTERN EUROPE: CARDIAC MAPPING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 23 WESTERN EUROPE: CARDIAC MAPPING MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 24 WESTERN EUROPE: CARDIAC MAPPING MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 25 EASTERN EUROPE: CARDIAC MAPPING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 26 EASTERN EUROPE: CARDIAC MAPPING MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 27 EASTERN EUROPE: CARDIAC MAPPING MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 28 ASIA-PACIFIC: CARDIAC MAPPING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 29 ASIA-PACIFIC: CARDIAC MAPPING MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 30 ASIA-PACIFIC: CARDIAC MAPPING MARKET, BY END USER, 2020-2027 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA: CARDIAC MAPPING MARKET, BY PRODUCT, 2020-2027 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA: CARDIAC MAPPING MARKET, BY INDICATION, 2020-2027 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA: CARDIAC MAPPING MARKET, BY END USER, 2020-2027 (USD MILLION)  

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CARDIAC MAPPING MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CARDIAC MAPPING MARKET

FIGURE 4 GLOBAL CARDIAC MAPPING MARKET SHARE, BY PRODUCT, 2020 (%)

FIGURE 5 GLOBAL CARDIAC MAPPING MARKET SHARE, BY INDICATION, 2020 (%)

FIGURE 6 GLOBAL CARDIAC MAPPING MARKET SHARE, BY END USER, 2020 (%)

FIGURE 7 GLOBAL CARDIAC MAPPING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 7 AMERICAS: CARDIAC MAPPING MARKET SHARE BY REGION, 2020 (%)

FIGURE 8 NORTH AMERICA: CARDIAC MAPPING MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 9 EUROPE: CARDIAC MAPPING MARKET SHARE, BY REGION, 2020 (%)

FIGURE 10 WESTERN EUROPE: CARDIAC MAPPING MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 11 ASIA-PACIFIC: CARDIAC MAPPING MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 12 MIDDLE EAST & AFRICA: CARDIAC MAPPING MARKET SHARE, BY COUNTRY, 2020 (%)

FIGURE 13 GLOBAL CARDIAC MAPPING MARKET: COMPANY SHARE ANALYSIS, 2020 (%)

FIGURE 14 ABBOTT LABORATORIES: KEY FINANCIALS

FIGURE 15 ABBOTT LABORATORIES: SEGMENTAL REVENUE

FIGURE 16 ABBOTT LABORATORIES: REGIONAL REVENUE

FIGURE 17 GE HEALTHCARE: KEY FINANCIALS

FIGURE 18 GE HEALTHCARE: SEGMENTAL REVENUE

FIGURE 19 GE HEALTHCARE: REGIONAL REVENUE

FIGURE 20 HILL-ROM SERVICES, INC.: KEY FINANCIALS

FIGURE 21 HILL-ROM SERVICES, INC.: SEGMENTAL REVENUE

FIGURE 22 HILL-ROM SERVICES, INC.: REGIONAL REVENUE

FIGURE 23 MEDTRONIC PLC.: KEY FINANCIALS

FIGURE 24 MEDTRONIC PLC.: SEGMENTAL REVENUE

FIGURE 25 MEDTRONIC PLC.: REGIONAL REVENUE

FIGURE 26 KONINKLIJKE PHILIPS N.V.: KEY FINANCIALS

FIGURE 27 KONINKLIJKE PHILIPS N.V.: SEGMENTAL REVENUE

FIGURE 28 KONINKLIJKE PHILIPS N.V: REGIONAL REVENUE

FIGURE 29 BIOTRONIK: KEY FINANCIALS

FIGURE 30 BIOTRONIK: SEGMENTAL REVENUE

FIGURE 31 BIOTRONIK: REGIONAL REVENUE

FIGURE 32 BOSTON SCIENTIFIC CORPORATION: KEY FINANCIALS

FIGURE 33 BOSTON SCIENTIFIC CORPORATION: SEGMENTAL REVENUE

FIGURE 34 BOSTON SCIENTIFIC CORPORATION: REGIONAL REVENUE

FIGURE 35 LIVANOVA PLC: KEY FINANCIALS

FIGURE 36 LIVANOVA PLC: SEGMENTAL REVENUE

FIGURE 37 LIVANOVA PLC: REGIONAL REVENUE

FIGURE 38 NIHON KOHDEN CORPORATION: KEY FINANCIALS

FIGURE 39 NIHON KOHDEN CORPORATION: SEGMENTAL REVENUE

FIGURE 40 NIHON KOHDEN CORPORATION: REGIONAL REVENUE

FIGURE 41 SCHILLER AG: KEY FINANCIALS

FIGURE 42 SCHILLER AG: SEGMENTAL REVENUE

FIGURE 43 SCHILLER AG: REGIONAL REVENUE

FIGURE 44 JOHNSON & JOHNSON: KEY FINANCIALS

FIGURE 45 JOHNSON & JOHNSON: SEGMENTAL REVENUE

FIGURE 46 JOHNSON & JOHNSON: REGIONAL REVENUE

FIGURE 47 SIEMENS HEALTHINEERS: KEY FINANCIALS

FIGURE 48 SIEMENS HEALTHINEERS: SEGMENTAL REVENUE

FIGURE 49 SIEMENS HEALTHINEERS: REGIONAL REVENUE

FIGURE 50 LEPU MEDICAL: KEY FINANCIALS

FIGURE 51 LEPU MEDICAL: SEGMENTAL REVENUE

FIGURE 52 LEPU MEDICAL: REGIONAL REVENUE

FIGURE 53 COREMAP: KEY FINANCIALS

FIGURE 54 COREMAP: SEGMENTAL REVENUE

FIGURE 55 COREMAP: REGIONAL REVENUE

FIGURE 56 KARDIUM, INC.: KEY FINANCIALS

FIGURE 57 KARDIUM, INC.: SEGMENTAL REVENUE

FIGURE 58 KARDIUM, INC.: REGIONAL REVENUE

FIGURE 59 CATHETER PRECISION, INC.: KEY FINANCIALS

FIGURE 60 CATHETER PRECISION, INC.: SEGMENTAL REVENUE

FIGURE 61 CATHETER PRECISION, INC.: REGIONAL REVENUE

FIGURE 62 EPMAP-SYSTEM: KEY FINANCIALS

FIGURE 63 EPMAP-SYSTEM: SEGMENTAL REVENUE

FIGURE 64 EPMAP-SYSTEM: REGIONAL REVENUE

Cardiac Mapping Market

The Global Cardiac Mapping Market is estimated to be USD 4.19 Billion growing at CAGR of 8.9% during forecast period of 2022-2030

Segmentation

By Product Contact Cardiac Mapping Systems Non Contact Cardiac Mapping Systems
By Indication Atrial Fibrillation Atrial Flutter Avnrt
By End User Hospitals Clinics Diagnostic Centers

Key Players

  • Abbott Laboratories
  • GE Healthcare
  • Boston Scientific Corporation
  • Medtronic plc.
  • Johnson & Johnson
  • Koninklijke Philips N.V.
  • Hill-Rom Services Inc

Drivers

  • Manufacturers focusing on R&D to introduce refined products in the market are expected to fuel the market growth
Speak to Analyst Request a Free Sample

Cardiac Mapping Market Synopsis


Cardiac mapping refers to the process of identifying the temporal and spatial distributions of myocardial electrical potentials during a heart rhythm. Normal functioning of the heart is affected by the presence of clots in blood vessels, aging, injury, and other lifestyle habits. Each day an average adult human heart beats 100,000 times and pumps about 2,000 gallons of blood.  

According to WHO, an estimated 17.9 million people died from cardiovascular diseases in 2016, representing 31% of all global deaths. This creates a huge demand for cardiac mapping devices to diagnose abnormal heart rhythms. 

Cardiac Mapping Market Influencer

An aging population and increasing incidence of cardiovascular diseases is expected to propel the cardiac mapping market.

Cardiac Mapping Market Drivers



  • Manufacturers focusing on R&D to introduce refined products in the market are expected to fuel the cardiac mapping market growth



  • The high prevalence of cardiac disorders such as coronary artery diseases, arrhythmias, congenital heart diseases, and cardiomyopathy is expected to increase the number of market entrants contributing to the growth of the cardiac mapping market. According to the CDC, one person dies every 37 seconds in the US from cardiovascular disease



  • Favorable reimbursement scenario coupled with increasing awareness among the geriatric population regarding cardiovascular diseases has anticipated the drive the growth. For instance, Medicare & Medicaid Services (CMS) proposed rule on the revisions to Medicare payment policies under the Physician Payment Schedule for the calendar year (CY) 2020, published on August 14, 2019, Federal Register (Vol. 84, No. 157 FR, pages 40482-41289)



  • The emergence of non-invasive 3D cardiac mapping systems is predicted to surge the cardiac mapping market size during the forecast period



Cardiac Mapping Market Restraints



  • Lack of trained electrophysiologists and cardiothoracic surgeons might impede the growth of the cardiac mapping market. The lack of healthcare infrastructure in developing countries and capital requirement for equipment can obstruct the growth


Cardiac Mapping Market Segmentation

By Product


  • Contact Cardiac mapping systems: This segment includes electroanatomical mapping, basket catheter mapping, and traditional endocardial mapping. The contact cardiac mapping systems segment is expected to hold a larger revenue share in the cardiac mapping market.




  • Non-contact Cardiac mapping systems: The non-contact mapping system consists of a catheter mounted multielectrode array which serves as the probe, a custom-designed amplifier system, and a computer workstation that is used to display three-dimensional maps of cardiac electrical activity.



By Indication


  • Atrial Fibrillation: Atrial fibrillation is an irregular and often rapid heart rate that occurs when the two upper chambers of heart experience chaotic electrical signals. According to the CDC, between 2.7 million and 6.1 million people in the US have Atrial Fibrillation. As the U.S. population ages, this number is expected to increase. In 2017, it was mentioned on 166,793 death certificates and was the underlying cause of death in 26,077 of those deaths. This segment holds the most significant share by revenue.

  • Atrial Flutter: Atrial flutter is a condition where the atria of the heart rapidly and regularly beat due to an anomaly in the heart's electrical system that usually results in a tachycardia

  • AVNRT: AV-nodal reentrant tachycardia (AVNRT) is an abnormally fast heart rhythm. It is a type of supraventricular tachycardia (SVT), meaning that it originates from a location within the heart above the bundle of His.

  • Wolff-Parkinson-White Syndrome: Wolff-Parkinson-White (WPW) syndrome, an extra electrical pathway between the heart's upper and lower chambers causes a rapid heartbeat. The extra pathway is present at birth and rare.

  • Others: Others include atrioventricular reciprocating tachycardia, paroxysmal supraventricular tachycardia, premature ventricular contractions, and others.


By End-User


  • Hospitals: In 2018, the hospital's segment held the largest share in the cardiac mapping market as these centers are the primary locations for patients receiving diagnosis & treatment for arrhythmiasClinics: Outpatients mostly prefer the clinics for monitoring heart diseases and routine checkup

  • Diagnostic Centers: Many diagnostic centers provide screening tests for cardiovascular diseases. The primary negative factor affecting diagnostic centers is high competition, while the primary positive factor is a low revenue volatility

  • Others: Others include research and academic institutes


By Region


  • Americas: The Americas held the largest regional cardiac mapping market share in 2018. This is owing to the high prevalence of cardiovascular diseases and the rising intermittent need for diagnosis. Hypertension, obesity, substance abuse, kidney diseases, and other conditions give rise to heart diseases, which are on the rise in the region.

  • Additionally, the presence of many hospitals in the US is likely to support cardiac mapping market growth. The US has over 32,000 cardiologists and a favorable reimbursement scenario.

  • Europe: The need for cardiac mapping is high in this region due to the aging population constantly at risk from cardiac disorders. As per Eurostat in 2016, just under two fifths (38.7 %) of all deaths among the elderly population in the EU-28 were from circulatory diseases, compared with almost one quarter (23.8 %) from cancer and less than one-tenth (8.9 %) from respiratory diseases

  • Asia-Pacific: Asia-Pacific is the fastest-growing regional cardiac mapping market for cardiac mapping. It has the world’s largest population and rapidly developing the healthcare sector. The Eastern and South Eastern-Asia are facing population aging rapidly

  • Middle East & Africa: It is estimated to account for the least share of the global cardiac mapping market due to the limited development of healthcare facilities coupled with lack of awareness regarding various circulatory disorders


Cardiac Mapping Market Key Players



  • Abbott Laboratories

  • GE Healthcare

  • Hill-Rom Services, Inc.

  • Medtronic plc.

  • Koninklijke Philips N.V.

  • Biotronik

  • Boston Scientific Corporation

  • LivaNova PLC

  • Nihon Kohden Corporation

  • Johnson & Johnson




Report Scope:
Report Attribute/Metric Details
  Market Size   Significant Value
  CAGR   (2020-2027): Substantial CAGR
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Product, By Indication and By End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Abbott Laboratories, GE Healthcare, Boston Scientific Corporation, Medtronic plc., Johnson & Johnson, Koninklijke Philips N.V., Hill-Rom Services, Inc., and others.
  Key Market Opportunities   An aging population and increasing incidence of cardiovascular diseases is expected to propel the cardiac mapping market.
  Key Market Drivers

  • Manufacturers focusing on R&D to introduce refined products in the market are expected to fuel the market growth
  • The emergence of non-invasive 3D cardiac mapping systems is predicted to surge the market size during the forecast period


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Cardiac mapping is the process of identifying the temporal and spatial distributions of myocardial electrical potentials during a heart rhythm

    The product involved in Cardiac Mapping Market are Contact Cardiac Mapping Systems, Non-Contact Cardiac Mapping Systems

    The major key players of Cardiac Mapping Market are Abbott Laboratories, GE Healthcare, Boston Scientific Corporation, Medtronic plc., Johnson & Johnson, Koninklijke Philips N.V., Hill-Rom Services, Inc., and others.